Pathios Therapeutics
Pathios Therapeutics is a clinical-stage biotech developing first-in-class oral small molecule inhibitors of the acid-sensing GPCR GPR65 to reverse immunosuppression in solid tumours, with lead asset PTT-4256 in Phase 1/2 trials for advanced solid cancers.
- Company typePrivate
- Founded2017
- HeadquartersOxford, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pathios Therapeutics does
Pathios Therapeutics is a clinical-stage oncology and immunology company founded in 2017 and headquartered at Milton Park, Oxford, UK. The company develops first-in-class small molecule inhibitors of GPR65, an acid-sensing G protein-coupled receptor that drives immunosuppressive polarization of immune cells in the acidic tumour microenvironment. Its lead asset, PTT-4256, is an orally bioavailable, highly selective GPR65 inhibitor (IC50 < 1 nM in human macrophages, >500-fold selectivity over related receptors) that is being evaluated in the RAISIC-1 Phase 1/2 study in patients with advanced solid tumours in Australia, with first patient dosed in November 2024. The company also pursues CNS-penetrating GPR65 inhibitors for malignant brain tumours and is exploring neurodegenerative indications (Alzheimer's, vascular dementia, Parkinson's) supported by human genetic validation linking GPR65 coding variants to disease.
The company's core technology rests on human-genetics-led target validation (notably the GPR65 I231L coding variant, rs3742704) combined with proprietary small molecule chemistry and a partnership with Sygnature Discovery for GPCR medicinal chemistry. Pathios operates within the Molecule to Medicine (MTM) incubator ecosystem alongside sister companies ThirtyFiveBio, Grey Wolf Therapeutics, Melio Bio, Lucia Bio and Curlew Bio, sharing operational and bioinformatics infrastructure.
Pathios' business model is a licensing-and-partnership biotech model: it advances candidates through clinical proof-of-concept and intends to out-license or co-develop with a major pharmaceutical company for global commercialization. The company has raised approximately US$58M to date, including a $25M Series B in April 2024 that brought in Bristol Myers Squibb as a strategic investor alongside Canaan and Brandon Capital. It is pre-revenue with no commercial products, a sub-10-person team (per firmographic data), and primarily uses scientific conferences (AACR, SITC, ESMO, ASCO) and peer-reviewed publications as its marketing channels ahead of a future partnership transaction.
Pathios Therapeutics firmographics
Firmographics- Name
- Pathios Therapeutics
- Legal name
- Pathios Therapeutics Limited
- Website
- https://pathiostherapeutics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Pathios Therapeutics is a clinical-stage biotech developing first-in-class oral small molecule inhibitors of the acid-sensing GPCR GPR65 to reverse immunosuppression in solid tumours, with lead asset PTT-4256 in Phase 1/2 trials for advanced solid cancers.
- Ownership category
- akta.pro rank
Pathios Therapeutics industry classification
Industry- Product category
- Cancer Immunotherapy / Immuno-Oncology Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Pathios Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Pathios Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
Revenue model
- Pharmaceutical licensing and partnership: As a clinical-stage biotech, Pathios' revenue model centers on developing novel therapeutics through clinical validation, then out-licensing or partnering with larger pharmaceutical companies for commercialization. The company may receive milestone payments, upfront payments, royalties, and co-development funding from pharmaceutical partners.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Pathios Therapeutics product offering
Product offeringCore offering
Pathios Therapeutics is a clinical-stage biotech developing first-in-class, orally-bioavailable small molecule inhibitors of the acid-sensing G protein-coupled receptor GPR65 to reverse immunosuppressive polarization of immune cells in the tumor microenvironment. Its lead asset PTT-4256 is in a Phase 1/2 clinical trial (RAISIC-1) in patients with advanced solid cancers, with broader pipeline programs targeting neuro-oncology and neurodegenerative diseases.
Product overview
Pathios Therapeutics is a clinical-stage oncology and immunology company developing first-in-class small molecule inhibitors targeting GPR65, an acid-sensing G protein-coupled receptor. The company's primary product is PTT-4256, an oral, highly potent, and selective GPR65 inhibitor currently in Phase 1/2 clinical trials (RAISIC-1) for advanced solid tumors. The broader GPR65 Inhibitor Program encompasses additional therapeutic candidates being developed for cancer and neurological applications. Founded in 2017 and headquartered in Oxford, UK, the company leverages human genetics-led insights to address immune dysfunction in the tumor microenvironment and other diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- PTT-4256 Internally discovered, orally-bioavailable, highly potent (IC50 < 1 nM in human macrophages) and selective (>500-fold over related receptors) small molecule inhibitor of the acid-sensing GPCR GPR65 for cancer immunotherapy. Currently in Phase 1/2 clinical evaluation (RAISIC-1) in patients with advanced solid tumors, with planned combination expansion modules.
- GPR65 Inhibitor Program Pipeline of proprietary first-in-class small molecule GPR65 inhibitors designed to counteract GPR65-mediated immunosuppressive polarization of immune cells in the acidic tumor microenvironment, and to explore GPR65 inhibition in neuro-oncology and neurodegenerative diseases (Alzheimer's Disease, Vascular Dementia, Parkinson's Disease) using CNS-penetrant compounds.
Quantifiable outcome
- GPR65 inhibitor PTT-4256 demonstrated IC50 < 1nM in human macrophages with >500-fold selectivity over related receptors
- +3 more outcomes
Companies that use Pathios Therapeutics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Pathios Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pathios Therapeutics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered secondary and core.
- WeatherdensecondaryCollaboration on publication in Cancers journal examining role of GPR65 in renal cell carcinoma. Weatherden team contributed alongside Pathios researchers to the scientific publication.
- Molecule to Medicine (MTM)coreMTM is the drug discovery ecosystem that created and continues to incubate Pathios. Provides operational and R&D support. Tom McCarthy and Kirsty McCarthy created MTM which includes other portfolio companies including ThirtyFiveBio, Melio Bio, Lucia Bio, Curlew Bio, and Grey Wolf Therapeutics.
- University of NottinghamsecondaryCollaboration on £567K Innovate UK grant to optimize CNS-penetrating GPR65 inhibitors for treating malignant brain tumors. Researchers evaluating optimized compounds in preclinical brain cancer models including human ex vivo co-culture system of glioblastoma.
- University of OxfordsecondaryCollaboration on £350K Innovate UK Smart Grant to develop tools for translation of GPR65 inhibitors for treatment-resistant melanoma. Researchers from Department of Oncology at University of Oxford working with Pathios.
- Sygnature DiscoverycoreStrategic drug discovery partnership providing industry-leading expertise in GPCR bioscience and medicinal chemistry. Sygnature invested equity in Pathios alongside providing hit-to-lead programme support, computational chemistry, library design, synthesis, and medium throughput screening capabilities.
- University of Oxford - Department of OncologysecondaryPartnership to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages. Collaborating on developing clinical target engagement biomarkers and bioinformatics techniques.
- Australian Clinical Trial Sites and CROssecondaryPartnership with Australian clinical trial sites and contract research organizations for conduct of RAISIC-1 Phase 1/2 clinical trial under Australian TGA Clinical Trial Notification scheme.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Pathios Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Pathios Therapeutics social profiles
Digital presencePathios Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pathios Therapeutics leadership team
Management profileNumber of profiles
Profiles17 records
Pathios Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Pathios Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pathios Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pathios Therapeutics
What does Pathios Therapeutics do?
Pathios Therapeutics is a clinical-stage biotech developing first-in-class, orally-bioavailable small molecule inhibitors of the acid-sensing G protein-coupled receptor GPR65 to reverse immunosuppressive polarization of immune cells in the tumor microenvironment. Its lead asset PTT-4256 is in a Phase 1/2 clinical trial (RAISIC-1) in patients with advanced solid cancers, with broader pipeline programs targeting neuro-oncology and neurodegenerative diseases.
Is Pathios Therapeutics a public or private company?
Pathios Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pathios Therapeutics founded?
Pathios Therapeutics was founded in 2017. It employs 1 to 10 people.
Where is Pathios Therapeutics based?
Pathios Therapeutics is headquartered in Oxford, United Kingdom, in the Europe region.
How does Pathios Therapeutics make money?
One revenue line is on record: pharmaceutical licensing and partnership.
Does Pathios Therapeutics have an API?
No public API is recorded for Pathios Therapeutics.
What industry is Pathios Therapeutics in?
Pathios Therapeutics's product category is Cancer Immunotherapy / Immuno-Oncology Drug Development. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 541714 and its SIC code is 2833.